Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 13/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890402 | 0.94 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL5384236 | 0.87 | TSHR (0.45) | RAPGEF4ALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL5845349 | 0.87 | RAPGEF4 (0.52) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL2335362 | 0.85 | RAPGEF4 (0.50) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL2756366 | 0.82 | RAPGEF4 (0.57) | RAPGEF4ALDH1A1MAPTLMNAGAA | |
| SCHEMBL21015410 | 0.81 | MAPT (0.56) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL9598966 | 0.79 | MAPT (0.39) | ALDH1A1MAPTLMNAGAA | |
| SCHEMBL6065939 | 0.79 | RAPGEF4 (0.44) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| Bromide SCHEMBL813517 | 0.78 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL16378511 | 0.78 | L3MBTL1 (0.49) | RAPGEF4ALDH1A1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7125990-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-6888004-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040254382-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| US-20040225001-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1359916-A4 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1359916-A1 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020183375-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-05 | — | — | US | disclosed |
| WO-2002058704-A1 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225001-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | RAPGEF4 1485/4885ALDH1A1 2593/4885MAPT 2909/4885 |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | RAPGEF4 1485/4885ALDH1A1 2593/4885MAPT 2909/4885 |
| US-20020183375-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | RAPGEF4 1485/4885ALDH1A1 2593/4885MAPT 2909/4885 |
| US-20040254382-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | RAPGEF4 1485/4885ALDH1A1 2593/4885MAPT 2909/4885 |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | RAPGEF4 1485/4885ALDH1A1 2593/4885MAPT 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.